NURS 617 Final Exam - Pharmacotherapeutics | 2026 Update | Questions & Correct Answers with Detailed Rationales | Grade A | NP, APRN & Advanced Pharmacology Exam Prep PDF

INSTANT PDF DOWNLOAD — This is the comprehensive final exam preparation guide for NURS 617 - Pharmacotherapeutics (2026 Update), featuring questions and correct answers with detailed rationales. Designed for Nurse Practitioner (NP), Advanced Practice Registered Nurse (APRN), and graduate nursing students, this resource consolidates the critical pharmacotherapeutic knowledge required to master advanced pharmacology concepts and excel on the NURS 617 final exam. The guide is meticulously aligned with current clinical guidelines, evidence-based prescribing practices, and national certification exam blueprints (AANP, ANCC). This verified resource provides comprehensive coverage of key NURS 617 Pharmacotherapeutics topics, including: Pharmacokinetics (absorption, distribution, metabolism, excretion—ADME; bioavailability, first-pass effect, volume of distribution, half-life, steady-state, loading dose, maintenance dose); Pharmacodynamics (receptor theory, agonists vs. antagonists, partial agonists, inverse agonists, dose-response curves, potency, efficacy, therapeutic index, ED50, TD50, LD50); Pharmacogenomics (genetic variations affecting drug response—CYP450 polymorphisms, drug metabolism phenotypes—poor metabolizers, intermediate metabolizers, extensive metabolizers, ultra-rapid metabolizers; pharmacogenetic testing, personalized medicine); Drug-Drug Interactions (pharmacokinetic interactions—absorption, distribution, metabolism, excretion; pharmacodynamic interactions—additive, synergistic, antagonistic; clinically significant interactions—CYP450 inducers/inhibitors, P-glycoprotein interactions); Adverse Drug Reactions (Type A—augmented, predictable; Type B—bizarre, idiosyncratic; Type C—chronic; Type D—delayed; Type E—end-of-treatment; Type F—failure of therapy; adverse drug event reporting—MEDWATCH); Medication Safety (high-alert medications, look-alike/sound-alike drugs, tall man lettering, medication error prevention, five rights of medication administration, ISMP recommendations, safe prescribing practices); Drug Therapy Across the Lifespan (pediatric pharmacotherapy—developmental pharmacokinetics, weight-based dosing, off-label use; geriatric pharmacotherapy—polypharmacy, Beers Criteria, STOPP/START criteria, age-related pharmacokinetic/pharmacodynamic changes; pregnancy and lactation—FDA pregnancy categories (A, B, C, D, X), placental drug transfer, lactation risk categories; breastfeeding considerations); Cardiovascular Pharmacotherapy (antihypertensives—ACE inhibitors, ARBs, CCBs, beta-blockers, diuretics, alpha-blockers, centrally acting agents; antidysrhythmics—Class I-IV agents, amiodarone, digoxin; heart failure therapy—ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, SGLT2 inhibitors, ARNI (sacubitril/valsartan), digoxin, diuretics; anticoagulants—heparin, enoxaparin, warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban); antiplatelets—aspirin, clopidogrel, ticagrelor, prasugrel; thrombolytics—alteplase, tenecteplase; antilipemics—statins, ezetimibe, PCSK9 inhibitors, fibrates, niacin, bile acid sequestrants); Respiratory Pharmacotherapy (asthma/COPD—short-acting beta-agonists—albuterol, levalbuterol; long-acting beta-agonists—salmeterol, formoterol; inhaled corticosteroids—fluticasone, budesonide, beclomethasone; anticholinergics—ipratropium, tiotropium; leukotriene modifiers—montelukast, zafirlukast; methylxanthines—theophylline; monoclonal antibodies—omalizumab, mepolizumab, benralizumab; systemic corticosteroids—prednisone, methylprednisolone; antitussives, expectorants, decongestants, antihistamines); Endocrine Pharmacotherapy (diabetes mellitus—insulin types: rapid-acting, short-acting, intermediate-acting, long-acting; insulin analogs, human insulin; insulin administration, insulin pumps; oral antidiabetic agents—metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, alpha-glucosidase inhibitors, bile acid sequestrants; thyroid disorders—levothyroxine, liothyronine, methimazole, propylthiouracil; adrenal disorders—glucocorticoids: hydrocortisone, prednisone, dexamethasone, methylprednisolone; mineralocorticoids—fludrocortisone; adrenal insufficiency management; Cushing's syndrome management; growth hormone disorders—somatropin, pegvisomant; calcium/bone metabolism—bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), calcitonin, teriparatide, abaloparatide, denosumab, romosozumab, calcium supplements, vitamin D); Neurologic and Psychiatric Pharmacotherapy (antidepressants—SSRIs, SNRIs, TCAs, MAOIs, atypical antidepressants; antipsychotics—first-generation (typical): haloperidol, chlorpromazine, fluphenazine; second-generation (atypical): clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, lurasidone, brexpiprazole, cariprazine; mood stabilizers—lithium, valproate, carbamazepine, lamotrigine; anxiolytics—benzodiazepines (alprazolam, lorazepam, diazepam, clonazepam), buspirone; sedative-hypnotics—zolpidem, eszopiclone, zaleplon, ramelteon, suvorexant; ADHD medications—stimulants: methylphenidate, dexmethylphenidate, amphetamine salts, lisdexamfetamine; non-stimulants: atomoxetine, guanfacine, clonidine; Parkinson's disease—levodopa/carbidopa, dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (selegiline, rasagiline), COMT inhibitors (entacapone, tolcapone), amantadine, anticholinergics (benztropine, trihexyphenidyl); Alzheimer's disease—cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA antagonist (memantine); antiepileptic drugs—phenytoin, carbamazepine, valproate, lamotrigine, levetiracetam, topiramate, zonisamide, gabapentin, pregabalin, phenobarbital, primidone, ethosuximide; multiple sclerosis—disease-modifying therapies (interferon beta-1a, interferon beta-1b, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, ocrelizumab); opioid analgesics—morphine, hydromorphone, oxycodone, hydrocodone, fentanyl, methadone, meperidine, tramadol, codeine; opioid antagonists—naloxone, naltrexone, methylnaltrexone; nonopioid analgesics—acetaminophen, NSAIDs (ibuprofen, naproxen, ketorolac, celecoxib); migraine therapy—triptans (sumatriptan, rizatriptan), ergotamines, gepants, CGRP antagonists, CGRP monoclonal antibodies, preventive medications (beta-blockers, anticonvulsants, antidepressants); substance use disorders—alcohol use disorder (disulfiram, naltrexone, acamprosate); opioid use disorder (methadone, buprenorphine, naltrexone); nicotine dependence (nicotine replacement therapy—patch, gum, lozenge, inhaler, nasal spray; bupropion, varenicline); Infectious Disease Pharmacotherapy (antibiotics—penicillins: penicillin G, amoxicillin, ampicillin, piperacillin/tazobactam; cephalosporins: generations 1-5; carbapenems: meropenem, imipenem/cilastatin, ertapenem, doripenem; monobactams: aztreonam; macrolides: azithromycin, clarithromycin, erythromycin; tetracyclines: doxycycline, minocycline, tetracycline; aminoglycosides: gentamicin, tobramycin, amikacin; fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin; sulfonamides: trimethoprim-sulfamethoxazole; glycopeptides: vancomycin; oxazolidinones: linezolid, tedizolid; lipopeptides: daptomycin; polymyxins: colistin; antifungals—azoles: fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole; echinocandins: caspofungin, micafungin, anidulafungin; polyenes: amphotericin B, nystatin; flucytosine; terbinafine; antivirals—herpes simplex/varicella-zoster: acyclovir, valacyclovir, famciclovir; influenza: oseltamivir, zanamivir, baloxavir marboxil; hepatitis B: entecavir, tenofovir; hepatitis C: direct-acting antivirals (sofosbuvir, ledipasvir, daclatasvir, glecaprevir/pibrentasvir); HIV: antiretroviral therapy (NRTIs, NNRTIs, PIs, integrase inhibitors, entry inhibitors, CCR5 antagonists); COVID-19: remdesivir, nirmatrelvir/ritonavir (Paxlovid); antimalarials—chloroquine, hydroxychloroquine, artemisinin derivatives, atovaquone/proguanil, mefloquine, doxycycline; antitubercular agents—isoniazid, rifampin, rifabutin, rifapentine, ethambutol, pyrazinamide, bedaquiline, delamanid; Oncologic Pharmacotherapy (chemotherapy agents—alkylating agents (cyclophosphamide, cisplatin, carboplatin, oxaliplatin); antimetabolites (methotrexate, 5-fluorouracil, gemcitabine, cytarabine, capecitabine); antitumor antibiotics (doxorubicin, daunorubicin, bleomycin); plant alkaloids (vincristine, vinblastine, paclitaxel, docetaxel, etoposide); topoisomerase inhibitors (irinotecan, topotecan); hormonal therapy—tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), fulvestrant, leuprolide, goserelin, abiraterone, enzalutamide; targeted therapy—tyrosine kinase inhibitors (imatinib, erlotinib, gefitinib, osimertinib, crizotinib), BRAF inhibitors (vemurafenib, dabrafenib), MEK inhibitors (trametinib, cobimetinib), CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), PARP inhibitors (olaparib, niraparib, rucaparib); immunotherapy—checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, avelumab), CAR T-cell therapy, monoclonal antibodies (rituximab, trastuzumab, bevacizumab, cetuximab); Immunomodulators and Biologics (immunosuppressants—cyclosporine, tacrolimus, sirolimus, everolimus, mycophenolate mofetil, azathioprine; biologics—TNF-alpha inhibitors (infliximab, adalimumab, etanercept, certolizumab, golimumab), IL-6 inhibitors (tocilizumab, sarilumab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (ustekinumab, guselkumab, risankizumab), integrin inhibitors (natalizumab, vedolizumab), B-cell depleting agents (rituximab, ocrelizumab, ofatumumab); Gastrointestinal Pharmacotherapy (PPIs—omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole; H2 blockers—famotidine, ranitidine, cimetidine, nizatidine; antacids; sucralfate; misoprostol; antiemetics—ondansetron, granisetron, palonosetron, dolasetron; metoclopramide, prochlorperazine, promethazine, diphenhydramine, scopolamine, aprepitant; antidiarrheals—loperamide, diphenoxylate/atropine, bismuth subsalicylate; laxatives—bulk-forming (psyllium), osmotic (polyethylene glycol, lactulose, magnesium hydroxide), stimulant (bisacodyl, senna), stool softeners (docusate); IBD therapies—5-ASA compounds (mesalamine, sulfasalazine, olsalazine, balsalazide), corticosteroids, immunomodulators, biologics; Renal and Genitourinary Pharmacotherapy (diuretics—loop (furosemide, bumetanide, torsemide, ethacrynic acid); thiazide (hydrochlorothiazide, chlorthalidone, metolazone); potassium-sparing (spironolactone, eplerenone, triamterene, amiloride); osmotic (mannitol); carbonic anhydrase inhibitors (acetazolamide); antispasmodics for overactive bladder—oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium, mirabegron; BPH medications—alpha-blockers (tamsulosin, alfuzosin, doxazosin, terazosin), 5-alpha-reductase inhibitors (finasteride, dutasteride), PDE5 inhibitors (tadalafil); erectile dysfunction—PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), alprostadil; Reproductive and Women's Health Pharmacotherapy (hormonal contraceptives—combined oral contraceptives (COCs), progestin-only pills, transdermal patch, vaginal ring, injectable (DMPA), implants (etonogestrel), IUDs (levonorgestrel, copper); emergency contraception—levonorgestrel, ulipristal acetate; menopausal hormone therapy—estrogen therapy (ET), estrogen-progestin therapy (EPT); oxytocics—oxytocin, methylergonovine, carboprost, misoprostol; tocolytics—nifedipine, indomethacin, magnesium sulfate, terbutaline; infertility medications—clomiphene, letrozole, gonadotropins (FSH, LH, hMG, hCG), GnRH agonists/antagonists, metformin; endometriosis—GnRH agonists (leuprolide, goserelin), GnRH antagonists (elagolix, relugolix), progestins, danazol; Dermatologic Pharmacotherapy (topical corticosteroids—hydrocortisone, triamcinolone, clobetasol; topical antibiotics—mupirocin, clindamycin, erythromycin; topical antifungals—clotrimazole, miconazole, ketoconazole, terbinafine; topical retinoids—tretinoin, adapalene, tazarotene; acne therapies—benzoyl peroxide, salicylic acid, azelaic acid, dapsone; oral isotretinoin; psoriasis therapies—topical corticosteroids, vitamin D analogs (calcipotriene), topical retinoids, coal tar, salicylic acid; systemic therapies—methotrexate, cyclosporine, acitretin, apremilast, biologics; Pain Management and Palliative Care (WHO analgesic ladder—step 1: non-opioids (acetaminophen, NSAIDs); step 2: weak opioids (codeine, tramadol); step 3: strong opioids (morphine, hydromorphone, oxycodone, fentanyl); adjuvant analgesics—anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants (amitriptyline, nortriptyline, duloxetine, venlafaxine), topical agents (lidocaine, capsaicin), corticosteroids, bisphosphonates, calcitonin; breakthrough pain management—immediate-release opioids, transmucosal fentanyl products; palliative sedation—benzodiazepines, barbiturates, propofol; Herbal and Dietary Supplements (St. John's wort, echinacea, ginkgo biloba, ginseng, garlic, saw palmetto, glucosamine/chondroitin, fish oil/omega-3 fatty acids, vitamin D, calcium, iron, folic acid, vitamin B12, vitamin C, zinc, magnesium, melatonin, coenzyme Q10, turmeric/curcumin, milk thistle, black cohosh, evening primrose oil, valerian root, kava, SAMe, 5-HTP, creatine, caffeine, ephedra; supplement-drug interactions, safety concerns, regulation by FDA (DSHEA 1994); Medication Administration and Monitoring (routes of administration—oral (PO), sublingual (SL), buccal, rectal, topical, transdermal, ophthalmic, otic, nasal, inhaled, subcutaneous (subQ), intramuscular (IM), intradermal (ID), intravenous (IV), intraosseous (IO), intrathecal, epidural, intra-articular; IV infusion rates, IV push administration, central line administration, PCA pumps, epidural pumps, subcutaneous infusion pumps; therapeutic drug monitoring (TDM)—digoxin, lithium, phenytoin, carbamazepine, valproate, vancomycin, aminoglycosides, cyclosporine, tacrolimus; drug levels: peak, trough, therapeutic range, toxic range; medication reconciliation, medication history, medication adherence, patient education, shared decision-making). It features hundreds of exam-style questions including multiple-choice, select-all-that-apply (SATA), and clinical scenario-based questions. Each question includes verified answers with detailed rationales explaining the correct answer and clarifying common misconceptions, along with cognitive level tags (Bloom's Taxonomy: Remember, Understand, Apply, Analyze, Evaluate), clinical application notes, and evidence-based practice references. Sample Question — "A patient with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF) is being started on a new medication. Which of the following would be MOST appropriate for both conditions?" A) Pioglitazone B) Saxagliptin C) Empagliflozin D) Glimepiride. Correct Answer: C. Rationale: Empagliflozin is an SGLT2 inhibitor that has been shown to reduce cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or HFrEF. Pioglitazone may worsen heart failure, saxagliptin has been associated with increased risk of heart failure hospitalization, and glimepiride has no cardiovascular benefit. DOCUMENT ACCESS: This study guide is available as an instant digital download (PDF) immediately upon purchase. Fully text-searchable, printable, and accessible anytime through your user account. Trusted by thousands of NP and APRN students for NURS 617 Pharmacotherapeutics final exams, AANP and ANCC board certification preparation, and mastering the essential concepts of advanced pharmacology with a strong emphasis on evidence-based prescribing, medication safety, and clinical decision-making.